Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHAP QHP Formulary Coverage & Prior Auth | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealth Alliance Plan (HAP)Policy N/A

    Qualified Health Plan Prescription Drug Formulary / Coverage Criteria

    Customize your policy alerts

    Sign up for all Health Alliance Plan (HAP) policy alerts

    Know when Health Alliance Plan (HAP) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the prescription drugs covered for Qualified Health Plans (QHPs), how the formulary is organized, tiers, and coverage controls (prior authorization, quantity limits, step therapy, specialty pharmacy). Affects members and prescribing providers using HAP QHPs.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyQualified Health Plan Prescription Drug Formulary / Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateCurrent as of 1/1/2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests via forms at hap.org/providers and document medical necessity when drugs are marked PA, QL, ST, or SP.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6-7Formulary tiers described
    1/1/2026Formulary current date
    SPSpecialty pharmacy required
    PA / QL / STCoverage controls used
    280/moTobramycin QL

    Coverage Criteria and Formulary Placement

    General Coverage Criteria

    Covered when following general conditions are met

    Formulary coverage basics: Drug is covered if listed on the QHP formulary and the member meets applicable plan requirements; tier determines cost-sharing.

    Formulary applies to outpatient prescription drugs only; medical‑administered drugs are covered under the medical benefit (Tier 7).

    Coverage controls: Coverage may require prior authorization (PA), be subject to quantity limits (QL), step therapy (ST), or specialty pharmacy (SP) dispensing as noted on the formulary.

    Specific drugs list PA/QL/ST/SP flags in formulary entries.

    Product-specific coverage controls

    Coverage and utilization controls as listed per product — stance varies by drug and note

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyQualified Health Plan Prescription Drug Formulary / Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateCurrent as of 1/1/2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests via forms at hap.org/providers and document medical necessity when drugs are marked PA, QL, ST, or SP.
    SourceLink
    On This Page
    Coverage Criteria and Formulary PlacementFormulary Codes, Legends and Quantity ExamplesWhat Providers Must Do / Authorization & Fulfillment RulesLegend & DefinitionsStep Therapy ProgramQuantity Limits (Examples and Per-Drug Values)Where Drugs Are Dispensed / Specialty SourcingBackground and Policy Scope
    Formulary tiers and controls:
    Each drug entry lists a DRUG TIER and NOTES which may include PA, QL, SP, ALT, PF, ST indicating coverage controls; applicability depends on the individual product entry.

    This segment provides per-product tiering and utilization notes; no single enrollment or clinical criteria are given in this segment.

    Formulary coverage with utilization controls

    Coverage entries are subject to utilization controls; drugs listed are covered per formulary tier when associated requirements are met.

    General formulary conditions: Drug is subject to listed utilization controls (PA, SP, QL, ST, PF) as indicated on each line

    Specific clinical criteria not provided in this extract; prior authorization needed where PA indicated

    Formulary controls (PA / SP / QL)

    Coverage and utilization controls in this excerpt apply as follows when ALL noted controls are met

    Formulary control requirements: Product must be on formulary or have prior authorization when marked PA; specialty products (SP) must be dispensed through Pharmacy Advantage; quantity limits (QL) must not be exceeded.see QL entries

    This is an administrative formulary listing; individual medical necessity criteria are not included in this section

    The formulary applies to outpatient prescription drugs only; medications administered in a provider office or inpatient setting are medical-benefit drugs and generally not governed by this outpatient formulary. General exclusions include: drug products used for cosmetic purposes, over-the-counter medications (unless specifically listed), experimental drugs or investigational use, and replacement of lost or stolen medication. Check the member's Summary of Benefits and Coverage for plan-specific limits and cost-sharing.

    Items explicitly marked Non-Formulary on the drug list are treated as non-formulary for the pharmacy benefit. Members or prescribers may request a formulary exception; if approved the drug will be covered at the appropriate non‑formulary copayment and non‑formulary specialty approvals are limited to up to a 30‑day supply and may be required to be dispensed through the designated specialty pharmacy (Pharmacy Advantage).

    Many specific products are listed as Non-Formulary across therapeutic classes. Examples in this extract include inhaled/nebulized agents (e.g., tobramycin inhalation solution 300 mg/4 mL), certain IV antibiotics (e.g., ZEVTERA IV), and multiple antifungal and other agents (e.g., NOXAFIL oral suspension). Non‑formulary designation often appears together with notes such as SP (specialty channel) and QL (quantity limits).

    For antifungal agents the listing shows both formulary and non‑formulary statuses with utilization controls. For example, CRESEMBA entries include PA and specific QL values for IV and oral presentations, while NOXAFIL oral suspension 200 mg/5 mL is designated Non‑Formulary and includes ALT/PA/QL notes in the formulary excerpt.

    Non‑formulary listing implies restricted coverage: claims for non‑formulary drugs may be denied or require higher member cost sharing unless an exception is approved. Non‑formulary entries commonly trigger administrative actions such as prior authorization (PA), specialty sourcing (SP), or documentation of alternative therapies, and some approvals are limited to specialty dispensing through Pharmacy Advantage.

    Additional non‑formulary examples in respiratory and specialty categories include inhalers and nebulizer products (e.g., DUAKLIR PRESSAIR, STRIVERDI RESPIMAT, SYMBICORT, VENTOLIN HFA) and many high‑cost specialty injectables and blood derivatives that are shown as Non‑Formulary in the excerpt.

    A Non‑Formulary listing may effectively indicate exclusion from preferred tiers and that coverage will require either a formulary exception or adherence to the payer's alternative‑therapy routing. Where approved, Non‑Formulary specialty drugs may still be covered but typically at the highest specialty copayment and with specialty pharmacy dispensing and quantity limits applied.

    Numerous items across classes are explicitly labeled Non‑Formulary in the formulary excerpt (for example: NUZYRA, SEYSARA, certain doxycycline or minocycline formulations, and several oncology products). This designation signals they are not on preferred tiers and are subject to the plan's non‑formulary processes and any applicable PA/QL/SP requirements.

    The extract lists specific non‑formulary drug examples used in routine care, such as prenatal preparations (e.g., PRENATE ELITE) and cardiovascular agents (e.g., BRILINTA) that are annotated Non‑Formulary and include notes for covered alternatives and quantity limits.

    Non‑formulary inhalers and related respiratory products shown in the excerpt (for example DUAKLIR PRESSAIR, PERFOROMIST, SYMBICORT, VENTOLIN HFA) include ALT (covered alternatives) and QL annotations. Providers should follow the listed alternatives and document the rationale when requesting exceptions.

    Many specialty biologics and blood‑derivative products are identified as Non‑Formulary or are flagged with PA and SP requirements (examples: ADVATE, ALPROLIX, AFSTYLA, NOVOEIGHT). These entries routinely require prior authorization and specialty pharmacy routing and often include strict quantity limits (for example, QL = 1 unit per day for many factor products).

    Practical impact for providers: obtain prior authorization when a product is labeled PA, route specialty prescriptions to Pharmacy Advantage when labeled SP (contact and process noted in the formulary), and ensure documented justification when requesting a non‑formulary exception. Forms and instructions for PA or formulary exception requests are available on the payer website.

    Additional non‑formulary examples include bradykinin receptor antagonists and TTR amyloidosis agents (e.g., FIRAZYR, icatibant, VYNDAQEL, VYNDAMAX) which are shown as Non‑Formulary and also carry PA, SP and QL notes in the formulary excerpt.

    Exceptions and exclusions: Non‑formulary drugs are not guaranteed coverage; a prescriber or member may request a formulary exception and HAP clinical staff will evaluate the request. Per the formulary, replacement for lost or stolen medication and investigational/experimental uses are not covered even if the product is otherwise listed.

    Some non‑formulary entries include additional restrictions beyond the Non‑Formulary flag — for example, specialty channel sourcing (SP) or specific QL values — but the extract does not consistently include an explicit 'No Medical Necessity' (NMN) statement in every non‑formulary segment.

    The provided extract does not contain explicit blanket statements using the phrase 'not medically necessary' for listed drugs; instead, coverage limitations are expressed via formulary flags (PA, QL, SP, Non‑Formulary) and the documented exception process.

    Across the excerpt there are no single‑line NMN declarations; coverage decisions for non‑formulary items are governed by the exception and prior‑authorization processes documented elsewhere in the formulary and by clinical review.

    Formulary Codes, Legends and Quantity Examples

    Formulary control codesmixed
    PAPrior Authorization
    QLQuantity Limits
    STStep Therapy
    SPMust be obtained at Pharmacy Advantage (specialty pharmacy)
    HCRHealth Care Reform rules apply
    PFPartial Fill Program
    TDNew HAP members: one 30-day fill in first 90 days
    AGAge Restriction
    Selected listed drug entriesNDC|mixed
    penicillamine oral tablet 250 mglisted with DRUG TIER = 2; NOTES = PA; SP; QL (4 tablets per 1 day)
    ELMIRON ORAL CAPSULE 100 MGDRUG TIER = 4; NOTES = PA; QL (3 capsules per 1 day)
    leucovorin calcium oral tablet 5-25 mgDRUG TIER = 2
    mesna oral tablet 400 mgDRUG TIER = 2; NOTES = QL (6 Tablets per Day)
    MESNEX ORAL TABLET 400 MGDRUG TIER = Non-Formulary; NOTES = ALT (Covered Alternatives: Mesna 400mg tablet)
    VISTOGARD ORAL GRANULES 10 GRAMDRUG TIER = Non-Formulary; NOTES = SP
    Antihistamines and nasal/ophthalmic agentsNDC|mixed
    clemastine oral tablet 2.68 mgDRUG TIER = 2; alternate non-formulary branded CLEMSZA listed with ALT and QL
    cyproheptadine oral syrup 2 mg/5 mlDRUG TIER = 2
    hydroxyzine hcl oral tablet 25 mgDRUG TIER = 2; NOTES = QL (4 tablets per 1 day)
    bepotastine besilate ophthalmic drops 1.5 %DRUG TIER = 2; QL (0.2 ml per 1 day)
    azelastine nasal sprayDRUG TIER = Non-Formulary; NOTES = ALT; QL (1 gram per 1 day)
    cetirizine oral tablet 5-10 mgDRUG TIER = 2
    Cephalosporin antibioticsNDC|mixed
    cefadroxil oral capsule 500 mgDRUG TIER = 2
    cefazolin in dextrose IV piggyback 3 gram/150 mlDRUG TIER = 7
    cephalexin oral capsule 250-750 mgDRUG TIER = 2
    cefdinir oral capsule 300 mgDRUG TIER = 2
    ceftriaxone injection recon soln 2 gramDRUG TIER = 7
    Tobramycin / inhalation productsNDC|mixed
    tobramycin inhalation solution 300 mg/4 mlDRUG TIER = Non-Formulary; NOTES = SP; QL (280 ampules per 30 days)
    tobramycin with nebulizer inhalation solution 300 mg/5 mlNOTES = PA; SP; QL (280 ampules per 30 days)
    TOBI inhalation solution 300 mg/5 mlDRUG TIER = Non-Formulary; NOTES = SP
    Listed product strengths and identifiersmixed
    0.15%ZIRGAN OPHTHALMIC (EYE) GEL 0.15 % (product strength listed)
    5%ZOVIRAX TOPICAL CREAM 5 %
    200 mg/5 mlazithromycin oral suspension for reconstitution 200 mg/5 ml
    250 mg, 500 mg, 600 mgazithromycin oral tablet strengths
    200 mgfidaxomicin oral tablet 200 mg
    600 mglinezolid tablet 600 mg
    450 mgBAXDELA ORAL TABLET 450 MG
    200 mg, 550 mgXIFAXAN ORAL TABLET strengths
    3 gramfosfomycin tromethamine oral packet 3 gram
    100 mg, 50 mgdoxycycline hyclate oral capsule strengths
    1–10 of 11
    1/2
    Sample drug strength entries (not exhaustive)mixed
    200 MGODOMZO ORAL CAPSULE 200 MG
    100 MG, 150 MG, 50 MGOGSIVEO ORAL TABLET
    25 MG/MLOJEMDA ORAL SUSPENSION FOR RECONSTITUTION 25 MG/ML
    PALFORZIA strength levelsmixed
    1 MG - 240 MG (various levels)PALFORZIA oral capsule sprinkle (multiple levels)
    Formulary product list (no billing codes present in this section)mixed
    No codes listed
    Named product strength descriptorsmixed
    5 MG (74 TABS)ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS)
    2.5 MG, 5 MGELIQUIS ORAL TABLET 2.5 MG, 5 MG
    0.5 MGELIQUIS ORAL TABLET FOR SUSPENSION 0.5 MG
    Product strengths and formulations (examples)mixed
    400-12 MCG/ACTUATIONDUAKLIR PRESSAIR INHALATION AEROSOL POWDR BREATH ACTIVATED 400-12 MCG/ACTUATION
    100-5 MCG/ACTUATIONDULERA INHALATION HFA AEROSOL INHALER 100-5 MCG/ACTUATION
    20 MCG/2 MLPERFOROMIST INHALATION SOLUTION FOR NEBULIZATION 20 MCG/2 ML
    2.5-2.5 MCG/ACTUATIONSTIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION
    1,000 MGARALAST NP INTRAVENOUS RECON SOLN 1,000 MG
    68.8 MGRYPLAZIM INTRAVENOUS RECON SOLN 68.8 MG
    Formulary drug entries and notes (excerpt)mixed
    ADVATEADVATE INTRAVENOUS RECON SOLN (multiple unit sizes) - NOTES = PA; SP; QL (1 unit per 1 day)
    ADYNOVATEADYNOVATE INTRAVENOUS SOLUTION (multiple unit sizes) - DRUG TIER = Non-Formulary; NOTES = QL; SP
    AFSTYLAAFSTYLA INTRAVENOUS RECON SOLN (multiple unit ranges) - NOTES = PA; SP; QL (1 unit per 1 day)
    ALHEMO PENALHEMO PEN SUBCUTANEOUS PEN INJECTOR 60 MG/1.5 ML - DRUG TIER = Non-Formulary; NOTES = SP
    ALPHANATEALPHANATE INTRAVENOUS RECON SOLN (VWF-containing) - NOTES = PA; SP; QL (1 unit per 1 day)
    AMICAR (aminocaproic acid)AMICAR ORAL SOLUTION 250 MG/ML - DRUG TIER = Non-Formulary; NOTES = QL (237 units per 60 days)
    BENEFIXBENEFIX INTRAVENOUS RECON SOLN (multiple sizes) - NOTES = PA; SP; QL (1 unit per 1 day)
    COAGADEXCOAGADEX INTRAVENOUS RECON SOLN (250, 500 unit ranges) - NOTES = PA; SP
    ELOCTATEELOCTATE INTRAVENOUS RECON SOLN (multiple sizes) - NOTES = PA; SP; QL (1 unit per 1 day)
    HEMLIBRAHEMLIBRA SUBCUTANEOUS SOLUTION (multiple concentrations) - NOTES = PA; SP; QL (examples: 0.01 mL per day)
    1–10 of 15
    1/2
    Sample listed drug entriesmixed
    metoprolol tartrate oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mgDRUG TIER = 2
    nadolol oral tablet 20 mg, 40 mg, 80 mgDRUG TIER = 2
    nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mgDRUG TIER = 2; NOTES = QL (1 tablet per 1 day)
    pindolol oral tablet 10 mg, 5 mgDRUG TIER = 2
    Bradykinin receptor antagonistsmixed
    FIRAZYR SUBCUTANEOUS SYRINGE 30 MG/3 MLDRUG TIER = Non-Formulary; NOTES = SP; QL (0.01 ml per 1 day)
    icatibant subcutaneous syringe 30 mg/3 mlDRUG TIER = 5; NOTES = PA; SP; QL (0.01 ML per 1 day)
    TTR amyloidosis agentsmixed
    VYNDAQEL ORAL CAPSULE 20 MGDRUG TIER = Non-Formulary; NOTES = PA; SP; QL (4 capsules per 1 day)
    VYNDAMAX ORAL CAPSULE 61 MGDRUG TIER = Non-Formulary; NOTES = PA; SP; QL (1 capsule per 1 day)
    Cardiac miscellaneousmixed
    ranolazine oral tablet extended release 12 hr 1000 mg, 500 mgDRUG TIER = Non-Formulary; NOTES = QL (2 tablets per 1 day)
    CORLANOR ORAL TABLET 5 MG, 7.5 MGDRUG TIER = Non-Formulary; NOTES = ALT (Covered Alternatives: IVABRADINE TABLETS); QL (2 tablets per 1 day)
    Legend-level quantity limit examples
    Atropine ophthalmic QLQL 5 mL per 30 days
    Baqsimi nasal sprayQL 1 kit per fill
    Naloxone nasal sprayQL 2 doses per 90 days
    Baqsimi / Gvoke nasal injectors guidanceSome auto-injector/glucagon products are Non-Formulary and have QL and ALT notes (examples: GVOKE PFS, GVOKE HYPOPEN)
    Most actionable exampleAtropine ophthalmic — QL 5 mL per 30 days
    Specific drug quantity-limit examples
    Penicillamine 250 mgQL 4 tablets per day; Notes: PA; SP
    ELMIRON (pentosan) 100 mgQL 3 capsules per day; Notes: PA
    Hydroxyzine HCl 25 mgQL 4 tablets per day
    Bepotastine (bepotastine besilate) ophthalmic drops 1.5%QL 0.2 mL per day
    Tobramycin and ophthalmic quantity limits
    Tobramycin inhalation solution (300 mg/4 mL)QL 280 ampules per 30 days; Notes: SP (specialty) and some nebulizer presentations noted PA
    Tobramycin ophthalmic drops 0.3%QL 5 mL per fill
    TOBREX ophthalmic ointment 0.3%QL 1 tube per fill
    Most actionable exampleTobramycin inhalation solution — QL 280 ampules per 30 days (high-volume QL)
    Ocular and azithromycin quantity limits
    ZIRGAN ophthalmic gel 0.15%QL 5 GM per 30 days
    Azithromycin oral suspension 200 mg/5 mLQL 4 mL per day
    Azithromycin oral tablets (250/500/600 mg)QL 8 tablets per fill
    Most actionable exampleZIRGAN ophthalmic gel — QL 5 GM per 30 days
    Oral oncology quantity-limit examples
    BALVERSA oral tabletQL 2 tablets per day; Notes: PA; SP
    CABOMETYX oral tabletQL 30 tablets per 30 days; Notes: PA; SP
    BOSULIF (various strengths)QL varies by strength (examples: 3 capsules/day or 1 capsule/day depending on strength); Notes: PA; SP
    Most actionable exampleCABOMETYX — QL 30 tablets per 30 days
    Additional oncology oral quantity limits
    ODOMZO oral capsule 200 mgQL 30 capsules per 30 days; Notes: PA; SP
    QINLOCK oral tablet 50 mgQL 3 tablets per day; Notes: PA; SP
    VENCLEXTA starting packQL 42 tablets per 30 days (starting pack); Notes: PA; SP
    Most actionable exampleVENCLEXTA starting pack — QL 42 per 30 days
    Vaccine and injector quantity limits
    SHINGRIX vaccineQL 1 mL per fill; Notes: HCR; AG (minimum 18 years as indicated)
    Epinephrine auto-injectors (various brands, e.g., EpiPen)QL 4 injectors per 30 days (4 units per fill)
    Naloxone / rescue kitsExamples show QL limits for rescue products (see naloxone QL 2 doses per 90 days)
    Most actionable exampleEpinephrine auto-injectors — QL 4 injectors per 30 days

    What Providers Must Do / Authorization & Fulfillment Rules

    Prior Authorization

    Prior authorization (PA) applies

    Certain drugs listed on the formulary are subject to Prior Authorization (PA); without PA the drug may not be covered and the prescriber must submit the PA request to HAP for clinical review.

    • PA is an administrative requirement that must be satisfied before coverage is approved.
    Prior Authorization

    PA required for flagged products (examples)

    Some specific products are flagged with 'PA' in the formulary notes and require the prescriber to obtain prior authorization before dispensing (examples shown in formulary entries).

    • Example: penicillamine oral tablet 250 mg is listed with NOTES = PA; SP; QL (4 tablets per 1 day).
    • Example: ELMIRON oral capsule 100 mg is listed with NOTES = PA; QL (3 capsules per 1 day).
    Prior Authorization

    PA required for selected products (tobramycin, CRESEMBA)

    Selected products include a PA note in their entry and require prior authorization before coverage; examples include tobramycin formulations and CRESEMBA.

    • Tobramycin with nebulizer: NOTES = PA; SP; QL (280 ampules per 30 days).
    • CRESEMBA oral capsule 186 mg: NOTES = PA; QL (70 capsules per 1 fill).
    Prior Authorization

    PA required for specified products (additional examples)

    Multiple other formulary lines are annotated 'PA' indicating prior authorization is required for coverage of those products.

    • CRESEMBA IV recon soln 372 mg: QL (0.01 Vial per 90 of Treatment per 180 Days) and SP noted.
    • PAXLOVID oral tablets: NOTES = PA; QL (5 days of treatment per 180 days).
    Prior Authorization

    PA required for HIV/HCV and other agents

    HIV/HCV agents and other antiviral/antiretroviral entries include PA or SP annotations — providers must obtain PA when the NOTES field indicates.

    • DESCOVY entries note PA and covered-alternative (ALT) information.
    • Several HCV agents (e.g., HARVONI, ledipasvir-sofosbuvir) are marked SP and QL and may require PA.
    Prior Authorization

    PA required for oncology and specialty drugs

    Many oncology and other specialty drugs are annotated with 'PA' and will require prior authorization prior to coverage; prescribers must request PA for these agents.

    • Examples: BALVERSA (NOTES = PA; SP; QL), CABOMETYX (NOTES = PA; SP; QL).
    Prior Authorization

    PA annotation requires provider to request authorization

    Formulary entries routinely include a 'PA' annotation; when present the provider must submit a prior authorization request to HAP before dispensing.

    • The formulary legend defines PA = Prior Authorization and many product lines include this note.
    Prior Authorization

    PA required for many specialty drugs

    Numerous specialty and high-cost agents are annotated with PA and often SP; providers must obtain prior authorization and follow specialty dispensing processes for these drugs.

    • Examples include ODOMZO (NOTES = PA; SP; QL) and other oncology/specialty listings.
    Prior Authorization

    PA for immunoglobulins (IV/SC IG products)

    Many intravenous and subcutaneous immunoglobulin products are noted with 'PA' (and often SP and QL); prescribers must obtain PA for coverage and follow specialty channel requirements.

    • Examples: CUVITRU NOTES = PA; QL (0.01 ML per 1 day); GAMMAGARD listings include NOTES = PA; SP; QL.
    Prior Authorization

    Prior authorization required (TRELEGY ELLIPTA example)

    Specific products such as TRELEGY ELLIPTA are annotated 'PA' in the formulary and require prior authorization before coverage will be approved.

    • TRELEGY ELLIPTA NOTES = PA; TD; QL (1 DEVICE per 30 days).
    Prior Authorization

    PA required for assorted products (examples)

    Additional assorted products across therapeutic areas are marked with PA in the NOTES field; prescribers must request prior authorization where PA is shown.

    • Examples include TAGRISSO (NOTES = PA; SP; QL) and PALFORZIA entries marked SP/PA as noted in formulary.
    Prior Authorization

    PA required for select specialty and blood products

    Select specialty and blood-derivative products are annotated 'PA' (and often 'SP'); prescribers must obtain prior authorization to secure coverage and correct specialty sourcing.

    • Examples: ARALAST NP, PROLASTIN-C, ADVATE entries include NOTES = PA; SP; QL.
    Prior Authorization

    PA required for IV hemostatics and specialty agents

    Many intravenous hemostatic and other specialty agents include 'PA' in their formulary notes; the prescriber must obtain prior authorization before the plan will cover these agents.

    • ADVATE NOTES = PA; SP; QL (1 unit per 1 day); ALTUVIIIO NOTES = PA; SP; QL (0.01 Vial per 1 day).
    Prior Authorization

    PA requirement (CABLIVI, EVKEEZA examples)

    Certain named specialty agents (e.g., CABLIVI, EVKEEZA) require prior authorization and may also require specialty procurement through Pharmacy Advantage.

    • CABLIVI INJECTION KIT NOTES = PA; SP; QL (1 vial per 1 day).
    • EVKEEZA INTRAVENOUS SOLUTION NOTES = PA; SP.
    Prior Authorization

    PA required for selected specialty drugs (icatibant, VYNDAQEL, CAMZYOS, ATTRUBY)

    Selected specialty drugs such as icatibant, VYNDAQEL, CAMZYOS and ATTRUBY are listed with 'PA' — prescribers must secure prior authorization for these therapies.

    • VYNDAQEL NOTES = PA; SP; QL (4 capsules per 1 day).
    • icatibant NOTES = PA; SP; QL (0.01 ML per 1 day).
    Step Therapy

    Step Therapy (ST) applies — provider implication

    Step Therapy (ST) requires that a specified alternative drug(s) be tried first before the requested drug will be covered; providers must follow ST when it is indicated in the formulary notes.

    • ST = Step Therapy Required — trial of listed alternative(s) needed prior to coverage.
    Note

    Step therapy legend — ST defined

    The formulary legend defines ST as 'Step Therapy Required' and indicates ST flags on entries where step therapy applies.

    • Refer to the formulary legend for the ST definition and presence of ST flags.
    Step Therapy

    Step therapy may be required — provider must follow ST

    When an individual drug entry is marked 'ST' the prescriber must follow the step therapy requirement (attempt required alternatives) before the formulary agent will be covered.

    • Providers should document trials of required alternatives when submitting PA or exception requests where ST applies.
    Note

    Step therapy flag present in legend and entries

    The formulary includes an ST flag in its legend and on product entries where step therapy applies; providers must check entries and comply with ST edits.

    • ST appears as a program control in the formulary legend and on some product lines.
    Note

    ST reference — legend indicates ST applies

    The formulary's legend and header note that ST = Step Therapy Required; when present on a product the prior trial requirement applies though specific step sequences are not shown in this excerpt.

    • Check the full formulary or PA criteria for specific step requirements per product.
    Note

    Step therapy general note — ST indicated

    Some agents may be marked 'ST' in the header legend; individual drug lines may require step edits — providers should follow step therapy instructions when noted.

    • ST is a plan control flagged on the formulary; specifics are found in product-specific rules.
    Step Therapy

    ST noted in legend — may apply to listed drugs

    Drugs that show 'ST' in the policy legend may require a prior trial of alternatives; providers must adhere to those requirements where indicated on drug lines.

    • Example: some amlodipine-atorvastatin combinations are marked ST in the NOTES.
    Note

    Step therapy (legend) — ST defined and applies

    ST is defined in the formulary legend as 'Step Therapy Required' and may apply to some listed products; providers should confirm and follow any ST edits before prescribing.

    • If ST is present, document prior therapy trials when requesting PA or exceptions.
    Step Therapy

    Step therapy flag — ST may apply to listed products

    The ST flag is present in the plan controls and will apply to drugs annotated 'ST' in the formulary; prescribers must comply with step therapy requirements where present.

    • Some COPD/inhaled products include TD and ST annotations with listed alternatives that should be tried first.
    Step Therapy

    Step Therapy / Transition — some items include ST/TD and alternatives

    Products annotated 'ST' require following step therapy prior to coverage; examples in the formulary include WELCHOL and certain amlodipine-atorvastatin combinations.

    • WELCHOL NOTES = QL (1 unit per 1 day) and may be marked ST where indicated.
    Note

    Step therapy defined in legend

    The formulary explicitly defines ST = Step Therapy Required in its legend; where ST is shown the prescriber must try required alternatives first.

    • ST is a plan control; specific step sequences are shown in product-specific rules (not in this excerpt).
    Note

    ST applicable where noted in legend

    Where the formulary legend includes ST, that flag may be applied to products; providers must check individual entries and comply with step therapy requirements when present.

    • ST indicates prior trial of specified therapy is required.
    Note

    Step therapy legend — ST listed

    The formulary legend lists ST as a control; products marked ST require prior trial of alternatives and providers must follow the policy edits for coverage.

    • No specific step paths are provided in this extract — check product-level criteria.
    Note

    Step therapy flag present in formulary legend

    ST flags appear in the formulary legend and on some products; providers should verify ST status on the product line before prescribing and document prior therapies as required.

    • ST = Step Therapy Required; follow documented step edits when present.
    Step Therapy

    Step therapy requirements — examples where ST applies

    Step therapy applies to multiple products (examples include WELCHOL and some amlodipine-atorvastatin combinations); when ST is present the provider must attempt required alternatives first.

    • Amlodipine-atorvastatin entries include NOTES = TD; ST (Step Therapy Required); QL (1 tablet per 1 day).
    Documentation Required

    How to request prior authorization or exception

    To request a prior authorization or formulary exception, the prescriber must submit the required forms and rationale via the portals/forms available at hap.org/providers.

    • The prescriber must explain why formulary requirements should not apply when requesting an exception.
    Note

    Authorization note definitions (PA/QL/SP)

    The formulary legend defines authorization notes: PA = Prior Authorization; QL = Quantity Limits; SP = obtainable only at Pharmacy Advantage (specialty pharmacy).

    • Use the legend to interpret PA, QL, SP, ST and other administrative flags on product lines.
    Documentation Required

    Standard PA/SP documentation — document indications

    When submitting PA or dispensing SP products, prescribers and pharmacies must document the clinical indication and support required by the PA process and adhere to specialty pharmacy sourcing when indicated.

    • Documentation should support medical necessity and any required trials of alternatives.
    Billing Rule

    Quantity limits enforced (example PAXLOVID)

    Quantity limits shown on many formulary entries will be enforced at claim adjudication; providers must not exceed noted QL or obtain PA/exception where clinically justified.

    • Example: PAXLOVID NOTES = PA; QL (5 days of treatment per 180 days).
    Note

    Formulary legend and administrative flags — provider implication

    The formulary legend lists administrative flags (PA, QL, SP, HCR, ST, PF, TD, AG) which appear next to many drugs; providers must follow payer procedures associated with these flags when prescribing or requesting authorization.

    • Ensure claims include required annotations and supporting documentation per the flag definitions.
    Billing Rule

    Specialty pharmacy sourcing — use Pharmacy Advantage for SP items

    Products marked 'SP' must be obtained via Pharmacy Advantage (specialty pharmacy) — providers should route prescriptions to Pharmacy Advantage when SP is indicated and include PA documentation as required.

    • Pharmacy Advantage contact: (800) 456-2112; SP fills are limited to up to a 30-day supply at a time.
    Documentation Required

    Specialty pharmacy routing — route SP items correctly

    Specialty medications flagged 'SP' must be obtained through Pharmacy Advantage; providers must follow specialty routing and include PA documentation to avoid denials or sourcing issues.

    • SP indicates specialty fulfillment only; up to 30 supply at a time.
    Prior Authorization

    Follow PA & specialty sourcing processes

    Providers must follow PA processes for drugs labeled 'PA' and procure specialty products via Pharmacy Advantage when 'SP' is indicated; failure to follow these processes may result in denial.

    • Submit PA requests and route SP prescriptions to Pharmacy Advantage with supporting documentation.
    Documentation Required

    Required administrative actions — follow plan procedures

    Administrative flags adjacent to drug entries (PA, QL, SP, HCR, ST, PF, TD, AG) are defined in the legend and must be followed; providers should consult these flags when prescribing and include required documentation.

    • Claims may be denied or require higher cost-share if flags are not followed.
    Billing Rule

    Required annotations on claims for flagged products

    When product notes include PA, QL or SP, providers must ensure claims/requests include the appropriate annotations and support; vaccine and specialty items commonly include these flags.

    • Document age restrictions (AG) and HCR requirements for preventive vaccines where indicated.
    Documentation Required

    Document alternatives and site when dispensing

    If a product entry shows 'ALT' or 'SP', providers should document the selected alternative and the site/source when dispensing or requesting authorization.

    • Document covered alternatives (ALT) when using them in place of non-formulary agents.
    Documentation Required

    Document quantity limits and alternatives

    When a product entry indicates QL or ALT, prescriptions should document applicable quantity and covered-alternative considerations to support PA or claim adjudication.

    • Example: Duaklir and ProAir entries include QL/ALT notes that should be recorded when prescribing.
    Documentation Required

    Documentation required for PA and QL

    Providers must supply documentation supporting medical necessity when requesting PA for products with QL or specialty sourcing notes; missing documentation may result in denial.

    • Documentation should reference applicable QL values and clinical rationale for exceeding limits if requested.
    Documentation Required

    Prior authorization and specialty pharmacy documentation required

    Many specialty or high-cost agents (e.g., CABLIVI, EVKEEZA) have PA and SP notes; prescribers must submit PA requests and procure these agents through the designated specialty channel to obtain coverage.

    • Failure to obtain PA or use Pharmacy Advantage for SP products can result in claim denial.
    Documentation Required

    PA and specialty sourcing — provider must comply

    Products marked PA require prior authorization; products marked SP must be obtained via Pharmacy Advantage (800-456-2112) as indicated in the formulary notes — providers must meet both requirements where shown.

    • Pharmacy Advantage is the designated specialty distributor for SP-marked items.
    Denial Risk

    PA required — denial risk if not obtained

    Drugs requiring prior authorization may not be covered without prior approval; PA requests must be submitted by the prescriber and will be evaluated by HAP clinical specialists.

    • If PA is not obtained, the claim may be denied at adjudication.
    Note

    PA and QL triggers — check product entries

    Prior Authorization (PA) and Quantity Limits (QL) are applied to specific listed products; providers should check product entries and obtain PA or adhere to QL to avoid coverage issues.

    • Examples: penicillamine NOTES = PA; SP; QL (4 tablets per 1 day); ELMIRON NOTES = PA; QL (3 capsules per 1 day).
    Denial Risk

    PA/SP and high QL items (tobramycin)

    Some inhalation products (notably tobramycin formulations) include PA and SP annotations plus high QL limits; failure to meet PA/SP or exceed QL may trigger denial.

    • Tobramycin inhalation solution NOTES = SP; QL (280 ampules per 30 days); tobramycin with nebulizer NOTES = PA; SP; QL (280 ampules per 30 days).
    Denial Risk

    Quantity limit and specialty routing enforcement — denial risk

    Requests exceeding specified quantity limits or not following required specialty pharmacy routing may be denied or not covered; providers must obtain PA or route through Pharmacy Advantage when required.

    • Example: exceeding 280 ampules per 30 days for tobramycin inhalation may lead to denial.
    Denial Risk

    PA required for selected antifungals (CRESEMBA)

    Coverage for some antifungals (e.g., CRESEMBA) may be restricted or denied without prior authorization; prescribers must request PA for these agents as noted.

    • CRESEMBA oral capsule 186 mg NOTES = PA; QL (70 capsules per 1 fill).
    Denial Risk

    Non-formulary products — restriction and exception process

    Non-formulary products listed on the formulary may be subject to coverage restrictions or require exception approval; providers should request exceptions when clinically necessary.

    • Non-formulary specialty drugs when approved may be required to be dispensed by Pharmacy Advantage and processed at the highest specialty copayment.
    Denial Risk

    Non-formulary / QL / PA exceedance — denial or higher cost-share risk

    Non-formulary items, failure to obtain PA, or exceeding QL can trigger denial or higher member cost-sharing; providers must document medical necessity and request exceptions when appropriate.

    • Exception approvals for standard non-formulary medications process at the highest non-specialty copayment; non-formulary specialty drugs process at the highest specialty copayment.
    Denial Risk

    Specialty products not sourced via SP may be denied

    Specialty products flagged 'SP' must be obtained via Pharmacy Advantage; claims for specialty drugs not sourced through the designated specialty channel may be denied.

    • Pharmacy Advantage contact: (800) 456-2112; SP fills limited to up to 30-day supply at a time.
    Prior Authorization

    Submit PA requests — denial risk if lacking PA

    Providers must submit PA requests for drugs annotated 'PA' — lack of PA at the time of claim adjudication may result in denial of coverage.

    • Many oncology and specialty agents include NOTES = PA; obtain PA before dispensing to avoid denials.
    Prior Authorization

    PA required for oncology specialty agents

    Oncology specialty drugs in the formulary frequently include PA and SP notes; prescribers must secure PA and follow specialty fill requirements to avoid claim denials.

    • Examples: many antineoplastic agents list NOTES = PA; SP; QL — follow PA process before dispensing.
    Denial Risk

    Lack of PA may result in denial

    If prior authorization is not obtained for drugs listed with 'PA' coverage may be denied or restricted; providers should confirm PA status prior to dispensing.

    • Coverage may be denied or restricted if PA is not obtained for PA-annotated drugs.
    Billing Rule

    PA/QL flags require authorization or are subject to limits

    Products flagged with PA and QL will either require prior authorization or will be limited by the specified quantity limits; providers must obtain PA if requesting quantities beyond QL.

    • SP flags indicate specialty sourcing via Pharmacy Advantage which may impact fulfillment and require coordination.
    Denial Risk

    PA/QL violations may trigger denial

    Products annotated with PA or QL may trigger denial if PA is not obtained or QL is exceeded; prescribers should document clinical justification and submit PA for exceptions.

    • Example: dihydroergotamine injection solution is listed with PA and QL; follow PA and QL rules to avoid denial.
    Denial Risk

    PA for blood derivatives and specialty agents — denial risk

    Products with PA or SP notes (including many blood derivatives and specialty agents) require prior authorization and specialty distribution; claims lacking required PA or SP routing may be denied.

    • Examples: ARALAST NP, GLASSIA, PROLASTIN-C list NOTES = PA; SP; QL.
    Denial Risk

    Coverage denial risk for non-formulary/ALT drugs

    Coverage may be denied for non-formulary products or when covered alternatives exist and no exception is approved; providers should request exceptions with clinical rationale when needed.

    • Example: BRILINTA is Non-Formulary with ALT: Ticagrelor — consider alternatives or request an exception.
    Denial Risk

    Specialty and PA noncompliance may cause denial

    Failure to meet prior authorization or specialty sourcing requirements for specialty products (PA/SP) may result in coverage denial; providers must both request PA and use Pharmacy Advantage when SP is indicated.

    • Example: FIRAZYR NOTES = SP; QL (0.01 ml per 1 day) — ensure PA/SP compliance to obtain coverage.
    Note
    Note

    Legend & Definitions

    Specialty drugs — definition
    Specialty drugs (definition)Brand, generic, or biosimilar drugs used to treat complex and/or chronic illnesses that require close supervision and monitoring; may be injectable/infusible or orally inhaled and often require prior authorization and dispensing through a contracted specialty pharmacy (Pharmacy Advantage).
    Specialty sourcingSpecialty drugs must be obtained via Pharmacy Advantage (800-456-2112) per formulary notes; up to a 30‑day supply at a time.
    Typical controlsSpecialty drugs commonly require PA, QL, and SP flags per formulary entries.
    Formulary tiers — tier structure and cost‑sharing
    Tier structureTier 1 = Select Generic; Tier 2 = Generic and Select Brand; Tier 3 = Preferred Brand; Tier 4 = Non‑Preferred Brand and Generic; Tier 5 = Preferred Specialty; Tier 6 = Non‑Preferred Specialty; Tier 7 = Medical coinsurance (medical‑administered drugs)
    Cost‑sharing impactTier determines member copay/coinsurance (higher tier = higher member cost).
    Specialty tiersPreferred Specialty (Tier 5) and Non‑Preferred Specialty (Tier 6) are for specialty drugs requiring contracted specialty pharmacy dispensing.
    Formulary legend — PA/QL/SP/ST/PF/ALT definitions
    PAPrior Authorization — prescriber must obtain approval before coverage
    QLQuantity Limits — maximum units allowed per specified period (per drug entry)
    SPSpecialty Pharmacy — obtainable only at Pharmacy Advantage (800‑456‑2112); up to 30 supply at a time
    STStep Therapy — Step Therapy Required when noted (try required alternatives first)
    PFPartial Fill Program
    ALTCovered Alternatives — alternate drugs listed may be required
    PA — abbreviation
    PAPA = Prior Authorization
    QLQL = Quantity Limits
    SPSP = Obtainable only at Pharmacy Advantage (specialty pharmacy)
    QL — abbreviation
    QLQL = Quantity Limits (per drug entry; expressed per day, per fill, per 30 days, or per treatment window)
    Examples of unitsTablets, capsules, mL, GM, vials, injectors, devices
    EnforcementQuantity limits are enforced at adjudication (e.g., PAXLOVID 5‑day course per 180 days)
    SP — abbreviation
    SPSP = Specialty Pharmacy — product must be obtained via Pharmacy Advantage (800‑456‑2112); up to 30 supply at a time
    Routing implicationPrescriptions for SP items must be routed to the designated specialty pharmacy for fulfillment
    Applies to many biologics/immunoglobulinsNumerous IV/SC immune globulins and specialty injectables are noted SP in the formulary
    ST — abbreviation
    STST = Step Therapy Required
    Operational noteWhen ST is noted, a required alternative must be tried before coverage is allowed; specific step sequences not listed in this excerpt
    ExamplesSome products (e.g., certain cholesterol and combo agents) are marked ST in the formulary
    Formulary notation definitions — PA/QL/SP
    PA (formulary notation)Prior Authorization — prescriber must obtain approval before coverage; appears next to many specialty and high‑cost drugs
    QL (formulary notation)Quantity Limits — maximum units allowed per time period as specified on each drug line
    SP (formulary notation)Specialty Pharmacy — requires dispensing via Pharmacy Advantage
    PA defined (legend short)
    PA (legend short)Prior Authorization
    NoteIndicates approval required prior to coverage
    ActionProviders must submit PA requests via HAP process
    QL defined (legend short)
    QL (legend short)Quantity Limits
    NoteSpecifies maximum allowed units/time for dispensing
    ActionClaims exceeding QL may be denied without PA/override
    SP defined (legend short)
    SP (legend short)Specialty Pharmacy — obtainable only at Pharmacy Advantage
    ContactPharmacy Advantage: 800‑456‑2112
    SupplyUp to 30 supply at a time per formulary notes
    PF — Partial Fill Program
    PF (Partial Fill Program)PF = Partial Fill Program — applied where noted in formulary entries
    PurposeSupports partial dispensing for specified products per program rules
    Example locationAppears in oncology and specialty product notes (e.g., PF listed for some oral anticancer agents)
    Tier definition — Tier 1–7
    Tier definitions (1–7)Tier 1 = Select Generic; Tier 2 = Generic/Select Brand; Tier 3 = Preferred Brand; Tier 4 = Non‑Preferred Brand/Generic; Tier 5 = Preferred Specialty; Tier 6 = Non‑Preferred Specialty; Tier 7 = Medical coinsurance (medical‑administered drugs)
    Specialty tiersTiers 5–6 are specialty tiers for drugs requiring close monitoring and specialty pharmacy dispensing
    Medical benefitTier 7 denotes medical‑administered drugs covered under medical benefit (coinsurance applies)
    PA (definition repeated)
    PA (repeated)Prior Authorization — approval required before coverage
    ImplicationClaims without PA for PA‑flagged drugs may be denied
    Provider actionSubmit PA requests per HAP process
    SP (definition repeated)
    SP (repeated)Obtainable only at Pharmacy Advantage; specialty dispensing required for SP items
    ContactPharmacy Advantage: 800‑456‑2112
    Supply limitUp to 30 supply at a time per formulary notes
    QL (definition repeated)
    QL (repeated)Quantity Limits — maximum units allowed per specified period as stated on each drug line
    ExamplesExpressed per day, per fill, per 30 days, or per treatment window
    EnforcementLimits are enforced at adjudication and may trigger denials
    Pharmacy Advantage contact and supply note for SP
    GAMMAGARD / CUVITRU examplesQLs for immunoglobulins vary by product (examples: GAMMAGARD 1 mL per 28 days; CUVITRU 0.01 mL per day); many require PA and SP
    Per‑day/per‑30‑day unitsImmunoglobulin QLs expressed as mL per day or per 28/30 days depending on formulation
    Provider actionObtain PA and route to Pharmacy Advantage when SP is indicated
    Administrative flags
    Administrative flags listCommon flags: PA, QL, ST, HCR, PF, TD, AG
    MeaningThese flags identify utilization controls or program rules appearing next to drug entries
    Provider implicationFollow documentation and submission requirements when flags are present
    PA (definition cluster)
    PA cluster (repeated)PA = Prior Authorization — appears widely across specialty and high‑cost drug entries
    Action requiredProviders must obtain PA before coverage for PA‑flagged products
    Denial riskClaims lacking PA may be denied at adjudication
    QL (definition cluster)
    QL cluster (repeated)QL = Quantity Limits — specified per drug line and enforced
    High QL examplesSome inhalation products (e.g., tobramycin) show high numeric QL values (280 ampules/30 days)
    DocumentationProviders should document medical need when requesting overrides
    SP (definition cluster)
    SP cluster (repeated)SP = Specialty Pharmacy channel requirement (Pharmacy Advantage)
    Contact and supplyPharmacy Advantage: 800‑456‑2112; up to 30 supply at a time
    Applies to biologicsApplies frequently to immunoglobulins and specialty injectables

    Step Therapy Program

    Policy featureDescription
    Step therapy (ST) flag on formularyIndicates that a member must try specified alternative drug(s) first before coverage of the requested drug will be allowed.
    ApplicabilityST applies to individual drug entries where 'ST' is noted in the formulary NOTES or legend.
    Operational effectCoverage is conditional on documented trial and failure or intolerance of required alternative(s) prior to approval of the requested agent.
    ItemDetail
    ST defined in legendST = Step Therapy Required (listed in the formulary legend).
    Specific step sequencesNo product-specific step sequences or ordered step paths are provided in the cited formulary excerpts; the legend only defines ST as a program flag.
    ContextImplication
    Legend and NOTES fieldStep therapy may be required where 'ST' is indicated in the NOTES field for individual drug entries; providers must follow ST when specified.
    Provider actionPrescribers should document prior trials of alternatives when requesting coverage for drugs flagged ST.
    ObservationNotes
    ST flag presentFormulary excerpts include 'ST = Step Therapy Required' as a program flag in the header/legend; specific flag presence is noted but per-drug detail not shown in these chunks.
    Supply channel info often adjacentST is shown alongside other administrative flags (PA, QL, SP) in the formulary legend entries.
    RuleApplication
    ST applies where indicatedThe legend states 'ST = Step Therapy Required' and ST applies to those formulary entries explicitly marked with ST; the excerpts reaffirm ST as an administrative control applied per product when present.
    DefinitionOperational note
    ST = Step Therapy RequiredDefined in the formulary legend; when 'ST' appears for a product the member is required to try specified alternative therapy(ies) before the requested product is covered.
    Header statementMeaning
    'ST = Step Therapy Required' in header/legendIndicates presence of step therapy program; specific per-product step requirements are not included in these excerpted header lines.
    Legend itemInterpretation
    ST indicated in legendThe legend includes ST among administrative flags; individual drug lines may require a prior trial of alternatives when ST is shown.
    FlagImplication
    ST flag definedST is a plan control flag in the formulary legend and may apply to some products though the cited segments do not include step paths or sequences.
    Example areaFormulary annotations
    COPD / inhaled productsSome COPD and inhaled products include 'TD' (transition) and 'ST' annotations and list covered alternatives; where ST is present prescribers must follow step edits before coverage.
    StatementClarification
    Step Therapy Required definedThe formulary legend explicitly lists 'ST = Step Therapy Required' though the specific step rules for individual products are not shown in these excerpts.
    Practice pointDetail
    ST may apply when notedWhen the NOTES field for a product includes 'ST', step therapy requirements apply; providers should document prior alternative therapy trials when requesting coverage or PA.
    Legend entryObserved limitation
    ST appears in legendThe legend lists ST but the excerpt does not include specific operational rules or ordered step sequences for products marked ST.
    FlagApplication
    ST flag existsST is a recognized administrative flag in the formulary; it may be applied to listed drugs where indicated, but the detailed step requirements are not present in these chunks.
    Products marked STExamples / implication
    Examples noted in extractThe brief and formulary indicate some products are marked ST (examples cited in inventory: WELCHOL and certain amlodipine-atorvastatin combinations); when ST is shown those products require step therapy prior to coverage.

    Quantity Limits (Examples and Per-Drug Values)

    Various QL examples — assorted drugs
    Assorted QL examples (overview)Examples include: atropine ophthalmic 5 mL per 30 days; Baqsimi 1 kit per fill; naloxone nasal spray 2 doses per 90 days; mesna QL 6 tablets per day; Elmiron QL 3 capsules per day
    Forms of limitsLimits expressed per fill, per day, per 30 days, or per 90/180 day treatment windows
    Enforcement noteThese QLs are enforced at claim adjudication and noted on formulary lines
    penicillamine oral tablet 250 mg — QL example
    Penicillamine oral tablet 250 mg (entry)QL = 4 tablets per day; NOTES = PA; SP
    TierDRUG TIER = 2 (per formulary entry)
    Covered alternativesALT lists penicillamine tablets as alternative on some entries
    ELMIRON oral capsule 100 mg — QL example
    ELMIRON oral capsule 100 mgQL = 3 capsules per day; NOTES = PA; DRUG TIER = 4
    ContextListed with chemotherapy antidote/protectant entries in formulary segment
    Provider implicationPA required before coverage; adhere to QL at dispensing
    hydroxyzine HCl oral tablet 25 mg — QL example
    Hydroxyzine HCl oral tablet 25 mgQL = 4 tablets per day
    Formulary tierDRUG TIER = 2 (per entry)
    NotesStandard antihistamine entry with per‑day QL
    tobramycin inhalation solution — QL examples
    Tobramycin inhalation solution (various)QL = 280 ampules per 30 days; NOTES = SP; some nebulizer combos include PA
    Tobramycin inhalation 300 mg/4 mLQL = 280 ampules per 30 days
    Per‑fill ophthalmic limitsTobramycin ophthalmic drops 0.3% QL = 5 mL per fill; TOBREX ointment QL = 1 tube per fill
    CRESEMBA and antifungal QL examples
    CRESEMBA IV recon soln 372 mgQL = 0.01 vial per 90 days of treatment per 180 days (0.01 vial per treatment window); NOTES = SP
    CRESEMBA oral capsule 186 mgQL = 70 capsules per fill; NOTES = PA
    Echinocandin examplesCaspofungin QL = 3 vials per 84 days of treatment in 180 days; micafungin QL = 1 vial per day
    PAXLOVID and XIFAXAN QL examples
    PAXLOVID oral tablets (dose pack)QL = 5 days of treatment per 180 days; NOTES = PA
    XIFAXAN 200 mgQL = 9 tablets per 30 days; NOTES = PA; SP
    XIFAXAN 550 mgQL = 60 tablets per 30 days; NOTES = PA; SP
    Antiretroviral QL examples
    Biktarvy (50-200-25 mg)QL = 1 tablet per day; NOTES = DRUG TIER = 5 for some strengths
    Emtricitabine‑tenofovir (TDF) formulationsQL = 1 tablet per day; NOTES = tiered specialty entries
    Stribild / Triumeq / OdefseyQL = 1 tablet per day for listed coformulations
    Aptivus QL example
    Aptivus 250 mgQL = 4 capsules per day
    Protease inhibitor class noteSeveral HIV protease inhibitors have per‑day QLs specified
    Provider implicationAdhere to QL and PA/SP requirements where noted
    Clindamycin topical QL example
    Clindamycin topical gelQL = 60 GM per 30 days
    Clindamycin topical lotion/solutionQL examples include 4 mL per day for some topical solutions
    AdherenceTopical antibiotic quantities limited per 30‑day period
    Oseltamivir QL example
    Oseltamivir capsulesQL = 10 capsules per fill (with up to 2 fills per 365 days for some presentations)
    Oseltamivir suspensionQL = 120 mL per fill (2 fills per 365 days)
    Neuraminidase inhibitor enforcementQLs applied during influenza season and per formulary entries

    Where Drugs Are Dispensed / Specialty Sourcing

    Note

    Outpatient applicability — pharmacy vs medical benefit

    The formulary applies to outpatient prescriptions — drugs administered in a medical setting are covered under the medical benefit (Tier 7); providers should route medical-administered drugs through the medical benefit.

    • Outpatient pharmacy drugs are governed by the formulary; medical-administered drugs are billed under the medical benefit (Tier 7).
    Billing Rule

    SP indicates obtainment via Pharmacy Advantage

    Products marked 'SP' must be obtained via Pharmacy Advantage; providers should direct patients/prescriptions to Pharmacy Advantage for specialty fills.

    • Pharmacy Advantage phone: (800) 456-2112; SP fills typically limited to up to a 30-day supply.
    Billing Rule

    Specialty pharmacy — obtain via Pharmacy Advantage

    Specialty products identified as 'SP' must be sourced from Pharmacy Advantage; prescribers should coordinate fulfillment through the designated specialty channel.

    • SP is defined as 'This can only be obtained at Pharmacy Advantage' in the formulary legend.
    Note

    SP = Pharmacy Advantage specialty pharmacy

    SP flag indicates specialty pharmacy sourcing through Pharmacy Advantage is required; providers must follow this sourcing instruction when the product entry includes SP.

    • Specialty routing may affect site of care and supply limits (up to 30-day supply).
    Billing Rule

    Specialty pharmacy = Pharmacy Advantage (contact provided)

    The formulary defines SP as specialty pharmacy obtained from Pharmacy Advantage (phone provided) and limited to up to a 30-day supply; providers must use this channel for SP-marked products.

    • Contact Pharmacy Advantage at (800) 456-2112 for specialty fills.
    Billing Rule

    SP items must be obtained via Pharmacy Advantage (contact provided)

    Products marked SP must be obtained via Pharmacy Advantage; the formulary notes the contact number and that specialty supplies are limited to up to a 30-day supply at a time.

    • Providers should include PA documentation and route prescriptions to Pharmacy Advantage for SP products.
    Billing Rule

    Infusion-center specialty sourcing — Pharmacy Advantage required

    Certain specialty drugs intended for infusion or complex administration must be obtained through Pharmacy Advantage (specialty channel); providers should coordinate with Pharmacy Advantage for infusion/medical-administered specialty products.

    • Infusion-center administered specialty products may still require SP sourcing and PA per formulary notes.
    Billing Rule

    SP must be obtained via Pharmacy Advantage (sourcing requirement)

    When a product is annotated SP, it must be obtained via Pharmacy Advantage specialty pharmacy; providers should ensure prescriptions and PA requests are routed accordingly to avoid fulfillment issues.

    • SP routing requirement appears throughout specialty and high-cost agent listings.
    Billing Rule

    SP indicates specialty fulfillment only via Pharmacy Advantage

    Formulary entries noted 'SP' indicate fulfillment only via Pharmacy Advantage; providers should contact Pharmacy Advantage for specialty dispensing instructions and ensure PA is submitted when required.

    • Pharmacy Advantage may direct the specific site or supplier for specialty products.
    Billing Rule

    SP routing and supply limits — contact Pharmacy Advantage

    Items annotated 'SP' must be obtained at Pharmacy Advantage (800-456-2112) and are typically limited to up to a 30-day supply; providers should coordinate with Pharmacy Advantage for specialty fills and documentation.

    • Providers should include PA documentation when submitting to Pharmacy Advantage.
    Billing Rule

    SP routing — Pharmacy Advantage handles specialty products

    Specialty products marked 'SP' are routed through Pharmacy Advantage; providers must use the specialty channel and submit required authorization documents to ensure coverage and fulfillment.

    • SP items often have accompanying QL that will be enforced by the specialty pharmacy.
    Billing Rule

    SP items obtained via Pharmacy Advantage or specialty distribution

    Products marked 'SP' may be obtained only via Pharmacy Advantage or specified specialty distribution; providers should coordinate procurement and authorization with Pharmacy Advantage for these items.

    • Many blood derivatives, immunoglobulins, and specialty injectables carry SP notes and require specialty sourcing.
    Billing Rule

    SP = obtain through Pharmacy Advantage (phone provided)

    When a drug is marked 'SP' the provider must obtain it through Pharmacy Advantage (phone provided); routing through the designated specialty pharmacy is required for coverage.

    • Providers should use Pharmacy Advantage contact (800-456-2112) for SP fulfillment and PA coordination.
    Billing Rule

    SP for infusion-center specialty items — procure via Pharmacy Advantage

    Specialty products noted with SP must be obtained via Pharmacy Advantage specialty channel; providers should route PA and prescriptions through the specialty channel to ensure coverage and proper sourcing.

    • Infusion-center administered specialty products may also require SP routing through Pharmacy Advantage.
    Billing Rule

    Infusion/specialty products — obtain via Pharmacy Advantage (contact)

    Certain specialty products require acquisition via Pharmacy Advantage; providers must contact Pharmacy Advantage (800-456-2112) and follow their specialty fill process to obtain these items.

    • Ensure PA is submitted and approved prior to ordering SP-designated specialty products.

    Background and Policy Scope

    Background: Specialty drugs are defined as biologics or other medications requiring close monitoring for safety and efficacy. The formulary notes that specialty products may require dispensing through the contracted specialty pharmacy (Pharmacy Advantage) and that these items frequently carry utilization controls such as PA and QL.